PL
BEAM icon

Polianta Ltd’s Beam Therapeutics BEAM Stock Holding History

Polianta Ltd’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,800
Closed -$514K – 75
2022
Q3 		$514K Buy
+10,800
New +$616K 0.42% 63
2022
Q2 		– Sell
-16,100
Closed -$922K – 71
2022
Q1 		$922K Buy
16,100
+800
+5% +$52.5K 0.6% 45
2021
Q4 		$1.22M Buy
+15,300
New +$1.31M 0.53% 54

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Polianta Ltd's BEAM Position: Q4 2022 in Review

Polianta Ltd sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 10,800 shares — an estimated $514K sold.

Polianta Ltd first reported a position in BEAM in Q4 2021 and held it in 3 quarters. The position peaked at $1.22M in Q4 2021. 207 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • Polianta Ltd reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Polianta Ltd sold 10,800 Beam Therapeutics shares in Q4 2022, an estimated $514K.
  • Polianta Ltd first reported a position in Beam Therapeutics in Q4 2021 and held it in 3 quarters.
  • Polianta Ltd's Beam Therapeutics position peaked at $1.22M in Q4 2021.
  • 207 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on Polianta Ltd's 13F filing for Q4 2022, filed 10 Jan 2023.